An evaluation of bicalutamide in the treatment of prostate cancer

@article{Schellhammer2002AnEO,
  title={An evaluation of bicalutamide in the treatment of prostate cancer},
  author={Paul Schellhammer},
  journal={Expert Opinion on Pharmacotherapy},
  year={2002},
  volume={3},
  pages={1313 - 1328}
}
Prostate cancer is a major health problem in men, causing significant morbidity and mortality. Although traditionally considered a disease of old age, improved diagnostic techniques have resulted in earlier diagnosis and many men are now treated while still physically and sexually active. Current therapies for prostate cancer, which include medical or surgical castration, have a significant impact on many aspects of quality of life. The non-steroidal antiandrogen bicalutamide (Casodex… Expand
Combination hormonal therapy: a reassessment within advanced prostate cancer
TLDR
The most recent meta-analysis by the Prostate Cancer Trialists' Collaborative Group indicates a small but statistically significant survival benefit with combination hormonal therapy using nonsteroidal antiandrogen. Expand
Combined androgen blockade: the case for bicalutamide.
TLDR
An analysis combining historic trial data suggests that bicalutamide 50 mg in addition to androgen deprivation may reduce the hazard ratio (HR) for prostate cancer mortality by 20% and has a number of advantages compared with nilutamide and flutamide when used in combination with castration. Expand
Quality of Life and Sexual Health in the Aging of PCa Survivors
TLDR
The present review summarized the current knowledge on the role of hormones, metabolic features, and primary treatments for PCa on the quality of life and sexual health of elderly Pca survivors. Expand
A HEPATOTOXICITY STUDY REGARDING BONE METASTASATED PROSTATE ADENOCARCINOMA HORMONOTHERAPY
The aim of the present study was to establish which therapeutical scheme used in the hormonotherapy (HT) of metastasated prostate adenocarcinoma at bone level was less hepatotoxic, on long-termExpand
Bicalutamide vs cyproterone acetate in preventing flare with LHRH analogue therapy for prostate cancer—a pilot study
TLDR
Bicalutamide is able to suppress the initial PSA surge as effectively as cyproterone acetate albeit slightly delayed, and a statement whether bicalUTamide is equally good at preventing clinical flare cannot be made. Expand
A review of estrogen receptor/androgen receptor genomics in male breast cancer.
TLDR
This review critically discusses the recent developments in the study of male breast cancer in relation to ERα and AR action and highlights the potential future studies to further elucidate the genomic regulation of this rare disease. Expand
Eliciting patient preferences for hormonal therapy options in the treatment of metastatic prostate cancer
TLDR
As expected, men with prostate cancer placed considerable importance on gains in survival; however, avoiding side effects of treatment was also clearly important; survival gains should be considered alongside side effects when discussing treatment options in metastatic disease. Expand
A selective androgen receptor modulator that reduces prostate tumor size and prevents orchidectomy-induced bone loss in rats
TLDR
The data show that selective androgen receptor modulators (SARMs) have the potential for anabolic effects on bone and muscle while maintaining therapeutic efficacy in prostate cancer. Expand
Androgen receptor modulators: a review of recent patents and reports (2012-2018)
TLDR
Development of nonconventional AR-modulating agents targeting NTD and DBD, is likely to be a promising approach to develop multiple and synergistic strategies able to overcome any kind of androgen-dependent condition. Expand
Orphan nuclear receptors as drug targets for the treatment of prostate and breast cancers.
TLDR
Discovery and development of small molecules that can bind at various functional sites on these ONRs will help determine their biological functions, and these molecules have the potential to act as prototypes for future drug development. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 91 REFERENCES
Is there a role for antiandrogen monotherapy in patients with metastatic prostate cancer?
TLDR
Patients with a higher disease burden (PSA >400 ng/ml) may decide that quality of life and symptomatic benefits outweigh the slight survival disadvantage seen in clinical trials and opt for bicalutamide monotherapy as an alternative to castration. Expand
A controlled trial of bicalutamide versus castration in patients with advanced prostate cancer.
TLDR
A comparison of pharmacologic effects showed that only the incidence of hot flushes was lower in the bicalutamide group, whereas breast tenderness and gynecomastia were more common, which translated into better quality of life during the first several months with regard to sexual relations and sexual functioning. Expand
Nonsteroidal antiandrogens: a therapeutic option for patients with advanced prostate cancer who wish to retain sexual interest and function
TLDR
In the absence of sexual interest, the treatment of sexual dysfunction becomes less relevant and therefore hormonal treatments for advanced prostate cancer which spare sexual interest are needed. Expand
Recent advances in the medical management of prostate cancer.
  • R. Kirby
  • Medicine
  • The British journal of clinical practice
  • 1996
TLDR
The development of hormone-refractory tumours is still a problem in advanced prostate cancer, although elucidation of the mechanisms involved should offer many potentially fruitful avenues for new therapies. Expand
Recent advances in the medical management of prostate cancer
TLDR
The development of hormone-refractory tumours is still a problem in advanced prostate cancer, although elucidation of the mechanisms involved should offer many potentially fruitful avenues for new therapies. Expand
Bicalutamide for advanced prostate cancer: the natural versus treated history of disease.
TLDR
The difference in outcomes for patients with androgen-independent progression suggests that the specific hormone therapy administered and the response to that therapy can influence the biology of the relapsing tumor and the sensitivity to subsequent therapies. Expand
The bicalutamide Early Prostate Cancer Program. Demography.
TLDR
This is the largest randomized clinical trial program to date in local prostate cancer and is expected to provide critical information on the role of bicalutamide as an addition to standard care for patients with local prostate cancers who have received a therapy of curative intent or are candidates for watchful waiting. Expand
Clinical Pharmacokinetics of the Antiandrogens and Their Efficacy in Prostate Cancer
TLDR
It is not yet clear if antiandrogen are of any benefit in downstaging the extent of disease before prostatectomy and/or radiotherapy, but some evidence exist that pure antiandrogens improve survival if combined with other forms of castration. Expand
Adjuvant Hormonal Treatment for Prostate Cancer: The Bicalutamide Early Prostate Cancer Program
TLDR
At the time of the most recently published analysis, the risk of objective clinical progression was significantly reduced in the bicalutamide arm, but further maturation of data is needed to see whether this difference will lead to a survival advantage. Expand
Are Non-Steroidal Anti-Androgens Appropriate as Monotherapy in Advanced Prostate Cancer?
TLDR
Preliminary findings indicate that flutamide may be as effective as orchidectomy in terms of prolonging progression-free survival in selected patients and bicalutamide is well tolerated as monotherapy and appears to be aseffective as castration in patients with locally advanced non-metastatic disease. Expand
...
1
2
3
4
5
...